TD Cowen says that Cerus (CERS)’ Intercept Fibrinogen Complex franchise represents an underappreciated long-term growth engine. The firm expects the newly announced BCA partnership to materially accelerate its adoption, scalability, and profitability across the U.S. blood center ecosystem. TD Cowen has increased confidence in the sustainability of Cerus’ double digit revenue growth trajectory and views the current discounted valuation as attractive. The firm has a Buy rating on the shares with a price target of $5.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERS:
- Cerus announces group purchasing pact with Blood Centers of America
- Cerus Corporation: Strong Q3 Growth Overshadowed by Regulatory Delays and Uncertainty
- Cerus Corporation’s Q3 2025 Earnings: Growth Amid Challenges
- Cerus’s Strategic Advancements and Financial Growth Highlight Undervalued Market Potential
- Cerus Corporation Reports Record Q3 2025 Earnings